These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26143137)

  • 1. Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib.
    Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
    Med Oncol; 2015 Aug; 32(8):213. PubMed ID: 26143137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
    Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice.
    da Cunha Vasconcelos F; Mauricio Scheiner MA; Moellman-Coelho A; Mencalha AL; Renault IZ; Rumjanek VM; Maia RC
    Leuk Res; 2016 Dec; 51():3-10. PubMed ID: 27770655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
    Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
    Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
    Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
    Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase.
    Malhotra H; Sharma P; Malhotra B; Bhargava S; Jasuja S; Kumar M
    Indian J Med Res; 2015 Aug; 142(2):175-82. PubMed ID: 26354214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
    Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
    Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
    Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
    Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
    J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
    Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
    Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
    Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.
    Wang L; Giannoudis A; Lane S; Williamson P; Pirmohamed M; Clark RE
    Clin Pharmacol Ther; 2008 Feb; 83(2):258-64. PubMed ID: 17568400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
    Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
    Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
    Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
    Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
    de Lima LT; Vivona D; Bueno CT; Hirata RD; Hirata MH; Luchessi AD; de Castro FA; de Lourdes F Chauffaille M; Zanichelli MA; Chiattone CS; Hungria VT; Guerra-Shinohara EM
    Med Oncol; 2014 Mar; 31(3):851. PubMed ID: 24469953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
    Jiang ZP; Zhao XL; Takahashi N; Angelini S; Dubashi B; Sun L; Xu P
    Pharmacogenomics; 2017 Jan; 18(1):35-56. PubMed ID: 27991849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.